AstraZeneca Pharma India informs about change in role of senior management personnel

20 Feb 2024 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed about the change in role of Amit Bhakri, currently the Business Unit Director - Biopharmaceutical Business Unit. He will be transitioning from the said role with effect from close of business hours on March 31, 2024, as he takes up another responsibility within AstraZeneca group. Further, it has informed that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Ayush Kumar Agarwal as Business Unit Director- Biopharmaceutical Business Unit with effect from April 1, 2024. Currently he is the Director – Commercial excellence and will continue leading the same in the interim till a replacement for the said position is filled. In this regard, it has enclosed the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 attached as Annexure – A.

The above information is a part of company’s filings submitted to BSE.

Astrazeneca Pharma I Share Price

5408.05 74.20 (1.39%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.